Core Viewpoint - Hanx Biopharmaceuticals (Wuhan) Co., Ltd. plans to issue up to 21,069,700 overseas listed ordinary shares and convert 117,897,830 domestic unlisted shares into overseas listed shares for trading on the Hong Kong Stock Exchange [1] Company Overview - Hanx Biopharmaceuticals is an innovative biotech company specializing in structural biology, translational medicine, and clinical development, with a focus on building an innovative pipeline since 2016 [1] - The company has developed a core product and nine other pipeline candidates, including three clinical-stage candidates targeting oncology (HX009, HX301, HX044) and seven preclinical candidates, which include antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies targeting autoimmune and oncology markets [1] Shareholder Information - A total of 15 shareholders will convert their shares, with the largest shareholding being 55,300,000 shares from Cai Zhang Biotechnology (Hangzhou) Co., Ltd. [2] - Other significant shareholders include Hanx Biopharmaceuticals (HK) Limited with 17,793,640 shares and Beijing Longpan Biopharmaceutical Venture Capital Center (Limited Partnership) with 12,860,470 shares [2] - The total number of shares being converted amounts to 117,897,830 shares [2]
翰思艾泰港股IPO及境内未上市股份“全流通”获中国证监会备案
Zhi Tong Cai Jing·2025-11-13 15:15